Efficacy and activity of treatments after progression from palbociclib plus endocrine therapy in patients with HR+/HER2– metastatic breast cancer: a prospective, monocentric study

Efficacy and activity of treatments after progression from palbociclib plus endocrine therapy in patients with HR+/HER2– metastatic breast cancer: a prospective, monocentric study

Background: Breast cancer is the most frequent tumour worldwide, and the HR+/HER2– subtype is the most common. For this tumour type, endocrine therapy (ET) is the mainstay of treatment. The association of ET and CDK4/6 inhibitors (CDK4/6i) represents the gold standard for first-line or second-line t...

Full description

Bibliographic Details
Main Authors: Raffaella Palumbo, Erica Quaquarini, Giuseppe Saltalamacchia, Alberto Malovini, Pietro Lapidari, Barbara Tagliaferri, Ludovica Mollica, Cristina Maria Teragni, Chiara Barletta, Laura Deborah Locati, Federico Sottotetti
Format: Article
Language:English
Published: BioExcel Publishing Ltd 2024-02-01
Series:Drugs in Context
Subjects:
endocrine resistance
metastatic breast cancer
palbociclib
post-progression
therapeutic strategies
Online Access:https://www.drugsincontext.com/efficacy-and-activity-of-treatments-after-progression-from-palbociclib-plus-endocrine-therapy-in-patients-with-hr-her2-metastatic-breast-cancer-a-prospective-monocentric-study/

Internet

https://www.drugsincontext.com/efficacy-and-activity-of-treatments-after-progression-from-palbociclib-plus-endocrine-therapy-in-patients-with-hr-her2-metastatic-breast-cancer-a-prospective-monocentric-study/

Similar Items